breast cancer

Oncology

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

News

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

News

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.